Key result
NHS–industry collaborative model maintains a ~11-week median referral-to-treatment time across 2,190 cardiac amyloidosis assessments.
Why the study?
Rising referral volumes, pathway variation, geographical access challenges, and newly available disease-modifying medicines for cardiac amyloidosis in the UK created a need for a scalable service model to support timely specialist assessment and treatment initiation.
Does a structured NHS–industry collaborative service redesign model accelerate access to specialist cardiac amyloidosis review and reduce referral to treatment timelines in elderly patients with cardiac amyloidosis?
Observational (n=2,190)
No
Does a structured NHS–industry collaborative service redesign model accelerate access to specialist cardiac amyloidosis review and reduce referral to treatment timelines in elderly patients with cardiac amyloidosis?
Answers are grounded in this paper and cite their sources.
An NHS–industry collaborative service redesign model successfully accelerated specialist review for 2,190 elderly cardiac amyloidosis patients and maintained a 10–12 week referral-to-treatment timeline despite rising demand.
Introduction Cardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy,1 where a delay in diagnosis can cause disease progression and an increased risk of morbidity and mortality2. Availability of approved disease modifying medicines for CA on the National Health Service (NHS), rising referral volumes, pathway variation and geographical access challenges in the UK, highlighted the need for a scalable service model to support timely patient assessment and appropriate treatment initiation. To address this care gap, a 12-month NHS-industry partnership was established, to accelerate specialist review of patients already diagnosed with CA and embed pathway improvements. Purpose To evaluate whether an NHS–industry collaborative model could accelerate access to specialist CA review, reduce referral to treatment timelines, and maintain operational reliability, within a high demand NHS service. Methods Between September 2024 and September 2025, a structured service redesign programme was implemented through an NHS-industry collaboration. The NHS Trust dedicated 5600 human resource hours (Table 1) and additional specialist diagnostics. The industry partner provided project management and funding for a clinical nurse specialist and data-capturer. Project components included, expedited clinical triage of previously diagnosed patients; expanded specialist capacity via additional clinics and remote assessments; standardised pathway controls (daily database audits, appointment reminders, same day clinical and pharmacy enquiry handling, and issue tracking); and operating procedures to support efficient review and initiation of appropriate disease modifying therapies where relevant. Real world data were collected prospectively to assess throughput, referral to treatment timelines and operational performance. Results Over a 12-month period, the pooling of NHS and industry resources facilitated the assessment and management of approximately 2,190 patients with CA mean age 77 years. In Phase 1, expedited clinical review was achieved within 3 months, for around 1,500 patients with CA already Trust registered. Previously, these individuals would have received annual reviews only. Phase 2 supported optimisation of the increasing influx of new referrals and further refined referral pathways. Despite increasing service demand, the median interval from referral to medication delivery was maintained at 10–12 weeks. Conclusion This NHS-industry collaboration delivered expedited system quality improvements, which benefitted patients, the NHS and the industry partner. This programme provides a scalable, transferable framework for CA service optimisation aligned with the NHS Long Term Plan and the UK Rare Diseases Framework priorities.3,4 Expanded specialist capacity, standardised pathway controls, and data driven oversight enabled expedited review and initiation of appropriate treatments, with sustained service resilience.
No takes yet. Share an insight, caveat, or question.
Gillmore et al. (2026) conducted an observational in Cardiac amyloidosis (n=2,190). NHS-industry collaborative service redesign programme vs. Standard prior service pathway (annual reviews) was evaluated on Throughput, referral to treatment timelines, and operational performance. An NHS–industry collaborative model facilitated assessment of ~2,190 cardiac amyloidosis patients over 12 months, maintaining a median referral-to-medication interval of 10–12 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: